[Observation of the serum acidic isoferritin levels in patients with hepatocellular carcinoma].
The levels of serum acidic isoferritin (SAIF) in 48 patients with hepatocellular carcinoma (HCC), 30 patients with hepatitis, 28 patients with liver cirrihosis, and 33 healthy subjects were measured by using enzyme-linked immunosorbent assay (ELISA--double-determinant). The result revealed that the SAIF values of HCC, HP and LC did not show normal distribution. The median values were 440 micrograms/L, 21 micrograms/L, 120 micrograms/L and, in normal subjects, 66 micrograms/L respectively. There were statistically significant differences between HCC and the control groups. The sensitivity of SAIF to HCC was 85.46%, with the cut-off point being 250 micrograms/L. SAIF was not correlated to AFP in HCC cases. The values of SAIF had no relationship with the volume of the tumors and the clinical stages. SAIF may be an available and useful serum marker and be beneficial to the diagnosis of early-staged HCC.